Designing and Conducting Effective Long-term Follow-Up Studies
About this webinar
Clinical trials often include an extended post-study follow–up period, ranging anywhere from months to years to assess the long-term impact of the treatment. Long-term follow up (LTFU) studies are undertaken to address the needs of the scientific community, regulators or both. The LTFU phase of a study has traditionally been part of a single clinical trial, but we are now seeing a decoupling of this phase into a stand-alone study.
While stand-alone LTFU studies are not new, the models have evolved with the advent of potentially transformative therapies and treatments, including, but not limited to advanced therapy medical products, cellular products and gene therapies. Sponsors are showing more interest in this specific type of study given new regulatory requirements, which in some cases call for 15 years of monitoring of patient outcomes and safety.
Register for this webinar to explore:
- Various models of LTFU studies and their applications
- Operational considerations to streamline the transition from clinical research to commercialisation in the current regulatory environment
Who should attend
- Clinical research
- Clinical development
- Patient outcomes
- Real-world evidence
- Cell and gene therapies
What you will learn
- Various models of LTFU studies and their applications
- Operational considerations to streamline the transition from clinical research to commercialisation in the current regulatory environment
Featured Speakers
Brandon Fletcher
Brandon is a Biochemist and Cancer Immunologist with roughly 30 years of research experience, specializing in hematology-oncology, rare disease and infectious disease. She has held roles in broad immune-oncology and cell and gene therapy research within academia and industry. Brandon is a collaborator with NCI’s origination of cancer CGTs and co-founded a global immune-oncology research training and support organization.
M. Christina Haas
Chris joined ICON in 2004 and is field-based near Munich, Germany and has held the position of Director, Project Management, Real World Evidence Late Phase Research, since 2013. Chris is responsible for providing Project Director oversight and governance to teams that manage, organize, and implement global late phase projects; overseeing managers that lead multidisciplinary cross-functional project teams from study start-up through to final product deliverable; and facilitating communications with clients. She has more than 24 years of experience in clinical research (phases II-IV) in both interventional and non-interventional studies on a global scale.
Partner for this event
ICON
ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON will operate from 150 locations in 47 countries and have approximately 38,000 employees as of July 1, 2021.
Related webinars
More from Icon.
Insights into first-in-human study design of oligonucleotides
When patients lead: Breaking barriers in ultra-rare disease drug development
ICH GCP E6(R3): Preparing for global implementation, assessing the impact, risk and requirements of the change
Becoming a sponsor of choice for high-performing sites
Riding the data wave: How pharma can navigate disruptions in open claims
Beyond the bench: The advantages of GMP over USP compounding in early phase development
Boosting clinical trial success in Alzheimer’s, Parkinson’s and other neurodegenerative diseases
Enhancing Clinical Trials in Obesity by Integrating Clinical Outcome Assessments and Digital Health Technologies
Introducing ICON Strategic Solutions FSP Services: How This Model Supports Sponsors in Korea
From Fragmented to Fluid: A Deep Dive into Claims Data Innovation
Get ready for a new wave of clinical trials in Schizophrenia: how Sites and Sponsors can avoid conceptual mistakes
Implementing digital health technologies for patient-centred trials